GLP-1 Agonists Show Strong Potential to Prevent Type 2 Diabetes in Prediabetes

Prediabetes is a critical metabolic state characterized by elevated blood glucose levels that are not yet high enough to be diagnosed as type 2 diabetes (T2D). It affects millions globally, significantly increasing the risk of progressing to T2D and developing cardiovascular disease. Current interventions often involve lifestyle modifications, but pharmacological options are increasingly explored. This review synthesizes the evidence on Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) as a potential therapeutic strategy to prevent T2D progression in individuals with prediabetes.

Pooled data from multiple studies consistently demonstrated that GLP-1 RAs significantly improve metabolic parameters in individuals with prediabetes. Treatment with GLP-1 RAs led to an average reduction in HbA1c (a measure of average blood sugar over 2-3 months) of 0.3% to 0.6% compared to placebo or lifestyle interventions alone. Furthermore, patients experienced substantial weight loss, averaging 5% to 10% of initial body weight, which is crucial for mitigating T2D risk. The most significant finding was a 45% to 70% reduction in the incidence of type 2 diabetes progression over 2-3 years in individuals treated with GLP-1 RAs compared to control groups. These benefits were observed across different GLP-1 RA compounds, with a generally favorable safety profile, primarily involving gastrointestinal side effects like nausea and vomiting in 10-30% of participants, which often attenuated over time.